Salpingoophorectomy

Momentis Announces First Adoption of Anovo™ Surgical System in Texas by Medical City Plano

Retrieved on: 
Monday, November 14, 2022
Salpingectomy, Technology, MD, Salpingoophorectomy, Ovarian cyst, Scar, Infection, FDA, Entrepreneurship, Shoulder, Elbow, Hysterectomy, Patient, CEO, Surgeon, Hospital, Dentistry

PLANO, Texas and FORT LAUDERDALE, Fla., Nov. 14, 2022 /PRNewswire/ -- Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Medical City Plano has acquired the Anovo™ Surgical System for use in transvaginal benign gynecological procedures including benign hysterectomies. Medical City Plano is the first medical facility in Texas to adopt this system.

Key Points: 
  • PLANO, Texas and FORT LAUDERDALE, Fla., Nov. 14, 2022 /PRNewswire/ -- Momentis Surgical Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Medical City Plano has acquired the Anovo Surgical System for use in transvaginal benign gynecological procedures including benign hysterectomies.
  • Medical City Plano is the first medical facility in Texas to adopt this system.
  • "We are pleased to see significant progress in bringing the Anovo Surgical System, the first surgical robot of its kind, to more healthcare facilities and patients across the U.S. including acute care hospitals such as Medical City Plano," said Dvir Cohen, CEO and Co-Founder of Momentis.
  • Momentis Surgical Ltd is a medical device company founded in 2013 and based in Tel Aviv, Israel with a wholly owned subsidiary, Momentis Surgical Inc., based in Fort Lauderdale, Florida.

Momentis Announces HCA Florida Northwest Hospital Acquires Anovo™ Surgical System

Retrieved on: 
Tuesday, October 11, 2022
Adoption, Joint Commission, Woman, Infection, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Hospital, Emergency medicine, Entrepreneurship, Salpingectomy, Scar, OBGYN, Spine, Food, Salpingoophorectomy, MD, Elbow, CEO, Pain, Safety, Level 3, Heart, FACS, FDA, Shoulder, Ovarian cyst, Surgeon, FACOG

MARGATE, Fla. and FORT LAUDERDALE, Fla., Oct. 11, 2022 /PRNewswire/ -- Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that HCA Florida Northwest Hospital has acquired the Anovo™ Surgical System for use in transvaginal benign gynecological procedures including hysterectomies. The Anovo System is the first and only FDA-authorized surgical robot with features including shoulder, elbow, and wrist joints designed to mimic human arms and provide human level dexterity.

Key Points: 
  • MARGATE, Fla. and FORT LAUDERDALE, Fla., Oct. 11, 2022 /PRNewswire/ -- Momentis Surgical Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that HCA Florida Northwest Hospital has acquired the Anovo Surgical System for use in transvaginal benign gynecological procedures including hysterectomies.
  • "We are pleased to have growing support from leading medical facilities in Florida including HCA Florida Northwest Hospital and hope to continue our momentum as we work to build broader commercial adoption of the Anovo System," said Dvir Cohen, CEO and Co-Founder of Momentis.
  • HCA Florida Northwest Hospital, an award-winning 289-bed acute care hospital, has served communities across northern Broward County and South Florida for more than 30 years.
  • HCA Florida Northwest Hospital is a part of HCA Florida Healthcare, the leading provider of healthcare in the state of Florida.

Momentis Announces Lee Health Adopts Anovo™ Surgical System for Robotic-Assisted Benign Gynecological Surgeries

Retrieved on: 
Tuesday, September 13, 2022
Ovarian cyst, Health, Gulf Coast Medical Center, MD, FDA, Entrepreneurship, Food, Salpingoophorectomy, Population, Operation, Infection, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Salpingectomy, Scar, Abdomen, CEO, Technology, Pain, Female, Surgeon, Hospital, Medical device, Medicine

FORT MYERS, Fla. and FORT LAUDERDALE, Fla., Sept. 13, 2022 /PRNewswire/ -- Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Lee Health has acquired the Anovo™ Surgical System, the first and only FDA-authorized surgical robot with features designed to mimic human arms and provide human level dexterity. The Anovo Surgical System will be available at Gulf Coast Medical Center. The Anovo System is designed to enable the less invasive vaginal approach for benign gynecological procedures including hysterectomies. The less invasive approach and improved dexterity position Anovo to provide a better surgical experience that may improve clinical outcomes and can be made available to a wider patient population.

Key Points: 
  • The Anovo System is designed to enable the less invasive vaginal approach for benign gynecological procedures including hysterectomies.
  • "Lee Health is pleased to offer the Anovo Surgical System as an option for our patients," said Jonathan Velez, MD, Chief Physician and Operations Executive at Gulf Coast Medical Center, a Lee Health hospital.
  • The Anovo System is indicated for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal.
  • A non-profit, integrated health care services organization, Lee Health is committed to the well-being of every individual served, focused on healthy living and maintaining good health.

Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA™ (oteseconazole) Capsules, the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

Retrieved on: 
Monday, July 18, 2022
Other Health, Research, Managed Care, General Health, Pharmaceutical, Consumer, Clinical Trials, Science, Women, Biotechnology, Other Science, Health, Half-life, History, Recurrence, CEO, Woman, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NOT, VVC, Communication, Person, Salpingoophorectomy, Capsule, Inflammation, Vaginal discharge, Food, Technology, Hypersensitivity, Insurance, Infertility, BCRP, Medication, Scott Richter, Incidence, Hysterectomy, Fetus, Commonwealth, Pain, Risk, Urination, Fungus, Enzyme, Candidiasis, Rosuvastatin, CYP51, FDA, Irritation, Toxicity, Education, CYP, Achievement, Pharmaceutical industry, Birth control

Potential appropriate patients for VIVJOA are women with RVVC who are postmenopausal or are permanently infertile due to a surgical procedure or for other reasons/conditions.

Key Points: 
  • Potential appropriate patients for VIVJOA are women with RVVC who are postmenopausal or are permanently infertile due to a surgical procedure or for other reasons/conditions.
  • To support effective two-way communication between patients and healthcare providers, we will encourage patients to ask their doctor if VIVJOA is right for them.
  • RVVC, also known as chronic yeast infection, is a distinct condition from vulvovaginal candidiasis (VVC) and defined as three or more symptomatic acute episodes of yeast infection in 12 months.
  • Mycovia Pharmaceuticals is an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies.

Mycovia Pharmaceuticals Announces Positive New Clinical Findings Evaluating VIVJOA™ (oteseconazole) Capsules in Patients with Recurrent Vulvovaginal Candidiasis (RVVC)

Retrieved on: 
Wednesday, June 22, 2022
Science, Women, Research, Pharmaceutical, Managed Care, Health, Consumer, Clinical Trials, Candidiasis, Population, Half-life, Hypersensitivity, FDA, Vaginal discharge, Irritation, Inflammation, Person, Scott Richter, Infertility, Enzyme, CYP, Capsule, Recurrence, Urination, Medication, NOT, Commonwealth, Disease, Rosuvastatin, Pain, Fungus, Korea Disease Control and Prevention Agency, VVC, History, Incidence, CYP51, Patient, Doctor of Philosophy, BCRP, Salpingoophorectomy, Toxicity, Hysterectomy, Center, Woman, Risk, Fetus, Pharmaceutical industry, Birth control

Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today shared topline results from evaluating VIVJOA (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC).

Key Points: 
  • Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today shared topline results from evaluating VIVJOA (oteseconazole) capsules in patients suffering from recurrent vulvovaginal candidiasis (RVVC).
  • Of the 71 patients enrolled in the observational extension study, 85% completed 96 weeks without a recurrent VVC episode.
  • The authors concluded that VIVJOA may play an important role in providing long-term reduction in the incidence of disease recurrence for women with RVVC.
  • VIVJOA (oteseconazole) capsules is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.

Mycovia Pharmaceuticals to Host Product Theater for VIVJOA™ (oteseconazole) During 2022 American College of Obstetricians and Gynecologists Annual Meeting

Retrieved on: 
Thursday, May 5, 2022
Research, Women, Infectious Diseases, FDA, Clinical Trials, General Health, Pharmaceutical, Consumer, Health, Science, BCRP, PDT, Specialization, Fetus, American College, Wayne, NOT, Woman, Toxicity, Rosuvastatin, ACOG, Medicine, Fungus, Infertility, Patient, Wayne State University School of Medicine, Half-life, Animal, Risk, FDA, Person, Hypersensitivity, Candidiasis, Incidence, Salpingoophorectomy, Scott Richter, Human, Enzyme, Center, Commonwealth, History, Adult, Salon, CYP51, Korea Disease Control and Prevention Agency, Dean, Medication, University School, Azole, CYP, American College of Obstetricians and Gynecologists, Hysterectomy, Recurrence, Pharmaceutical industry, Dietary supplement, Birth control, Gynaecology

Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company, will sponsor a product theater showcase for its recently FDA-approved VIVJOA (oteseconazole capsules), during the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting.

Key Points: 
  • Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company, will sponsor a product theater showcase for its recently FDA-approved VIVJOA (oteseconazole capsules), during the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting.
  • The session will be held at Salon 1 AB and open to all meeting attendees.
  • RVVC is a distinct condition from vulvovaginal candidiasis, and until recently, there have been no FDA-approved medications specifically indicated for it.
  • Nearly 75% of all adult women will have at least one yeast infection in their lifetime, with approximately half experiencing a recurrence.

Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Retrieved on: 
Wednesday, March 30, 2022
Private Securities Litigation Reform Act, Risk, Therapy, Rerun, Guinea, Ageing, Hormone replacement therapy, NKB, Flushing, Nasdaq, GLOBE, Disorder, Breast Cancer Research and Treatment, Annual report, UCD School of Medicine, Male, Security (finance), Peri, Drug development, IVMS, Maple syrup urine disease, Trial of the century, Marketing, Neurokinin B, Breast, Schizophrenia, Breast cancer, MSUD, U.S. Securities and Exchange Commission, Salpingoophorectomy, Neuron, Metabolism, III, Emetine, Pharmacokinetics, Clinical trial, CMO, Dopamine, Program, Flash, Schizoaffective disorder, Review, Microdeletion syndrome, Menopause, FDA, Synapse, Patient, Celiprolol, Vipul Ved Prakash, Hypothalamus, COL3A1, Research, Woman, VMS, Safety, COVID-19, Mutation, ACER, Depression, BRCA, Acquisition, Infection, Pharmaceutical industry, Birth control, MD, Acer

The trial is intended to enroll approximately 56 post-menopausal women aged 40-65, who experience moderate to severe hot flashes.

Key Points: 
  • The trial is intended to enroll approximately 56 post-menopausal women aged 40-65, who experience moderate to severe hot flashes.
  • Vasomotor symptoms, either induced or as part of peri- and post-menopause, are a significant and debilitating burden on patients.
  • We are excited to start evaluating the safety and efficacy of ACER-801 in this dose-ranging study in post-menopausal women with moderate to severe VMS.
  • We believe this study marks an important first step in finding a meaningful treatment for patients suffering from iVMS, said Adrian Quartel, MD, CMO of Acer.

Clinical Studies Demonstrate Patient Benefits of vNOTES Technique

Retrieved on: 
Wednesday, November 10, 2021
Research, Surgery, Medical Devices, Women, Hospitals, Clinical Trials, Health, Consumer, Science, American Association, Surgical Outcomes Analysis and Research, Education, Congress, American College of Obstetricians and Gynecologists, Growth, Gynecologic oncology, Horizon, Laparoscopy, Analgesic, Length of stay, MIS, Pain, AdventHealth, MBA, Literature, Research, Comparison, Association, Woman, AAGL, Systematic review, Hospital, Obstetrics, Patient, Surgeon, Bleeding, Female, Meta-analysis, Doctor of Philosophy, Sterilization, Vagina, Multimedia, Technique, Medicine, Salpingoophorectomy, History, Consultant, Journal, MIGS, Canadian International Council, American College, Obesity, Peritoneal cavity, Adoption, Sexual Offences Act 1956, FACOG, Anatomy, Patient satisfaction, ACOG, Adhesion, Birth control, Pharmaceutical industry, Dentistry

Clinical studies demonstrate the considerable patient benefits of the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique a new, modern approach to vaginal surgery.

Key Points: 
  • Clinical studies demonstrate the considerable patient benefits of the vaginal natural orifice transluminal endoscopic surgery (vNOTES) technique a new, modern approach to vaginal surgery.
  • Multiple studies cite improved patient outcomes and benefits, including shorter duration of surgery and length of stay, lower pain scores and total dose of analgesics, and higher patient satisfaction.
  • The following clinical studies highlight recent research about the vNOTES technique and mounting clinical evidence for its benefits to patients.
  • Expert panelists will discuss their diverse experience with the vNOTES technique, the clinical evidence and the associated patient outcomes.

Surgical Robots Market to surpass US$ 16,875.6 Mn by end of 2028, Says Coherent Market Insights

Retrieved on: 
Thursday, October 21, 2021
Intense, Hospital, RAS, Gross domestic product, Surgeon, Accessory nerve disorder, Conditional sentence, IMS, Partnership, Patient, Adoption, FDA, Salpingoophorectomy, SSI, IPL, Plastic, Laser, Centers for Medicare & Medicaid Services, Medtech, ASPS, Uterus, Tubing (recreation), Spinal cord injury, Medicare, Medtronic, RASD, Growth, Hugo, Prevalence, Artery, American Society of Plastic Surgeons, Society, GYN, Dentistry, Medical device

SEATTLE, Oct. 21, 2021 /PRNewswire/ -- Surgical robots are kinds of surgical practices which are carried out using specialized robotic surgical systems.

Key Points: 
  • SEATTLE, Oct. 21, 2021 /PRNewswire/ -- Surgical robots are kinds of surgical practices which are carried out using specialized robotic surgical systems.
  • Growing demand for minimally invasive surgical procedures is a prime factor driving growth of the surgical robots market .
  • Moreover, increasing regulatory approval for the introduction of surgical robots is again anticipated to accelerate growth of the market.
  • A growing number of gynecology surgeries is expected to provide enormous growth opportunities to the market of surgical robots.

Surgical Robots Market to surpass US$ 16,875.6 Mn by end of 2028, Says Coherent Market Insights

Retrieved on: 
Thursday, October 21, 2021
Intense, Hospital, RAS, Gross domestic product, Surgeon, Accessory nerve disorder, Conditional sentence, IMS, Partnership, Patient, Adoption, FDA, Salpingoophorectomy, SSI, IPL, Plastic, Laser, Centers for Medicare & Medicaid Services, Medtech, ASPS, Uterus, Tubing (recreation), Spinal cord injury, Medicare, Medtronic, RASD, Growth, Hugo, Prevalence, Artery, American Society of Plastic Surgeons, Society, GYN, Dentistry, Medical device

SEATTLE, Oct. 21, 2021 /PRNewswire/ -- Surgical robots are kinds of surgical practices which are carried out using specialized robotic surgical systems.

Key Points: 
  • SEATTLE, Oct. 21, 2021 /PRNewswire/ -- Surgical robots are kinds of surgical practices which are carried out using specialized robotic surgical systems.
  • Growing demand for minimally invasive surgical procedures is a prime factor driving growth of the surgical robots market .
  • Moreover, increasing regulatory approval for the introduction of surgical robots is again anticipated to accelerate growth of the market.
  • A growing number of gynecology surgeries is expected to provide enormous growth opportunities to the market of surgical robots.